Published in J Immunol on November 28, 2016
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 9.30
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature (2010) 7.50
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature (1997) 4.27
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J (2001) 2.37
A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med (2000) 2.30
Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med (2006) 2.21
A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med (2006) 2.15
Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther (2005) 2.06
A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med (2015) 1.87
Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci U S A (1995) 1.85
Origin of monocytes and macrophages in a committed progenitor. Nat Immunol (2013) 1.84
Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol (2002) 1.82
Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils. J Exp Med (1998) 1.75
BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med (2000) 1.61
Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol (2003) 1.54
Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol (2011) 1.41
IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther (2007) 1.40
Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis (1983) 1.35
Nonclassical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice. Cell Rep (2014) 1.30
Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. J Clin Invest (2011) 1.24
The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am J Pathol (2010) 1.19
Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol (2006) 1.17
Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res (2008) 1.15
An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol (2008) 1.13
Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford) (2012) 1.08
IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol (2011) 1.08
The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol (2007) 1.06
IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol (2008) 1.06
Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res (1996) 1.00
The leukotrienes: immune-modulating lipid mediators of disease. Adv Immunol (2012) 0.99
Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther (2009) 0.96
A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci U S A (2009) 0.84
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 0.84
Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis. J Immunol (2014) 0.84
5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front Pharmacol (2010) 0.83
Leukotriene B4 activates intracellular calcium and augments human osteoclastogenesis. Arthritis Res Ther (2014) 0.81
LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. Artif Cells Blood Substit Immobil Biotechnol (2005) 0.79
Natural products for treatment of bone erosive diseases: The effects and mechanisms on inhibiting osteoclastogenesis and bone resorption. Int Immunopharmacol (2016) 0.77
Promoting macrophage survival delays progression of pre-existing atherosclerotic lesions through macrophage-derived apoE. Cardiovasc Res (2015) 0.76